UNSPSC 51292006: Dapoxetine

This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C21H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GB2433A4M3, chemically known as benzenemethanamine, n,n-dimethyl-alpha-(2-(1-naphthalenyloxy)ethyl)-, (+)- but generally known as dapoxetine, which bears US NIH Compound Identifier 71353. European Medicines Agency schedules Dapoxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06908MIG.

UNSPSC 51292006 Dapoxetine is a Commodity code that in recent state and local procurement captures a broader pharmaceutical and therapeutic product category than its nominal scope suggests. Recent opportunities under this code show state and local governments procuring naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements, and exploring direct-to-manufacturer prescription programs. The mix of issuing bodies includes county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering contracts for multiple jurisdictions including Oregon). The code reflects activity in community health procurement, pharmacy benefit management initiatives, and bulk pharmaceutical supply arrangements where jurisdictions seek to standardize sourcing, control costs through negotiated pricing, and ensure regulatory compliance including FDA certification and Drug Supply Chain Security Act adherence.

Geographic activity appears concentrated in Florida, Texas, Minnesota, and Oregon, with multi-state cooperative vehicles extending reach across participating jurisdictions. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries and a two-year initial term; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring vendor capacity for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multi-vendor contracts for generic pharmaceuticals and OTC products through three authorized wholesalers with awards effective July 1, 2026. Cooperative purchasing vehicles dominate the landscape, with MMCAP requiring vendor compliance with cGMP, DSCSA, EDI capability, and 3 percent administrative fees on all purchases, while individual county and state procurements emphasize drug-free workplace certification, E-Verify compliance, and substantial insurance coverage including $5 million commercial general liability.